StudyGraphics #VisualAbstract Idecabtagene vicleucel demonstrates higher efficacy over currently available therapies in triple-class relapsed and refractory multiple myeloma July 1, 2021 | Kathleen Lau Facebook Twitter Pinterest WhatsApp Linkedin ReddIt Email Print RELATED ARTICLESMORE FROM AUTHOR #VisualAbstract: Dose-escalated concurrent chemoradiotherapy does not improve survival in locally advanced esophageal cancer #VisualAbstract Venetoclax with dose-adjusted EPOCH-R may be a promising combination therapy for aggressive B-cell lymphoma #VisualAbstract: Efficacy and safety of therapeutic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19
